Related Experiment Videos
Ezetimibe-induced hyperlipidaemia
Summary
Ezetimibe, a cholesterol absorption inhibitor, can paradoxically cause severe hypertriglyceridemia and hypercholesterolemia. This rare side effect, linked to increased hepatic cholesterol synthesis, may persist long after drug discontinuation.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Ezetimibe is a widely used cholesterol absorption inhibitor.
- It effectively lowers low-density lipoprotein-cholesterol (LDL-C) levels.
- Familial combined hyperlipidemia (FCH) is a common genetic disorder characterized by elevated cholesterol and triglycerides.
Observation:
- A case report details a patient with statin intolerance and FCH.
- The patient experienced a novel side effect from ezetimibe therapy.
- This side effect was a significant increase in lipid levels.
Findings:
- Ezetimibe therapy induced a 770% increase in triglycerides and a 190% increase in total cholesterol.
- This was secondary to a 560% increase in hepatic cholesterol (lathosterol) synthesis.
- The abnormal lipid profile resolved 9 months after discontinuing ezetimibe.
Implications:
- Ezetimibe monotherapy can induce severe mixed hyperlipidemia in susceptible individuals.
- This effect may be due to increased very-low-density lipoprotein (VLDL) synthesis.
- Ezetimibe's effects may be long-lasting, exceeding its plasma half-life.